JP2005507673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507673A5 JP2005507673A5 JP2003541439A JP2003541439A JP2005507673A5 JP 2005507673 A5 JP2005507673 A5 JP 2005507673A5 JP 2003541439 A JP2003541439 A JP 2003541439A JP 2003541439 A JP2003541439 A JP 2003541439A JP 2005507673 A5 JP2005507673 A5 JP 2005507673A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- set forth
- sequence set
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 229920001184 polypeptide Polymers 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 238000000034 method Methods 0.000 claims 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims 13
- 150000002632 lipids Chemical class 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000036490 Arterial inflammations Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003662 Atrial flutter Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010073734 Microembolism Diseases 0.000 claims 2
- 208000005228 Pericardial Effusion Diseases 0.000 claims 2
- 208000025584 Pericardial disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000004301 Sinus Arrhythmia Diseases 0.000 claims 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 208000033774 Ventricular Remodeling Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 238000005452 bending Methods 0.000 claims 2
- 230000036471 bradycardia Effects 0.000 claims 2
- 208000006218 bradycardia Diseases 0.000 claims 2
- 230000002308 calcification Effects 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 210000003709 heart valve Anatomy 0.000 claims 2
- 208000018578 heart valve disease Diseases 0.000 claims 2
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 claims 2
- 208000023589 ischemic disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 208000004124 rheumatic heart disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000008209 cardiovascular development Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33958201P | 2001-11-05 | 2001-11-05 | |
| PCT/US2002/035538 WO2003039341A2 (en) | 2001-11-05 | 2002-11-05 | Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507673A JP2005507673A (ja) | 2005-03-24 |
| JP2005507673A5 true JP2005507673A5 (enExample) | 2006-01-12 |
Family
ID=23329699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541439A Pending JP2005507673A (ja) | 2001-11-05 | 2002-11-05 | １３９、２５８、１２６１、１４８６、２３９８、２４１４、７６６０、８５８７、１０１８３、１０５５０、１２６８０、１７９２１、３２２４８、６０４８９または９３８０４を用いる心血管疾患を治療するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030119742A1 (enExample) |
| EP (1) | EP1450666A4 (enExample) |
| JP (1) | JP2005507673A (enExample) |
| AU (1) | AU2002360343A1 (enExample) |
| WO (1) | WO2003039341A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003266238A1 (en) * | 2002-08-05 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1) |
| EP1585815A4 (en) * | 2003-01-21 | 2006-02-22 | Bristol Myers Squibb Co | A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF |
| CN114377024B (zh) * | 2021-12-27 | 2023-10-24 | 南方医科大学南方医院 | 一种用于治疗和/或预防高血脂疾病的药物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912335A (en) * | 1996-10-03 | 1999-06-15 | Smithkline Beecham Corporation | G-protein coupled receptor HUVCT36 |
| US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| US20030175748A1 (en) * | 2000-09-27 | 2003-09-18 | Feder John N. | Novel human G-protein coupled receptor, HGPRBMY3, expressed highly in immune- and colon- related tissues |
| US20030186360A1 (en) * | 2000-09-27 | 2003-10-02 | Feder John N. | Novel human G-protein coupled receptor, HGPRBMY3, expressed highly in immune -and colon-related tissues |
-
2002
- 2002-11-05 EP EP02795592A patent/EP1450666A4/en not_active Withdrawn
- 2002-11-05 AU AU2002360343A patent/AU2002360343A1/en not_active Abandoned
- 2002-11-05 US US10/288,222 patent/US20030119742A1/en not_active Abandoned
- 2002-11-05 WO PCT/US2002/035538 patent/WO2003039341A2/en not_active Ceased
- 2002-11-05 JP JP2003541439A patent/JP2005507673A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morano | Tuning the human heart molecular motors by myosin light chains | |
| Cleynen et al. | The HMGA proteins: a myriad of functions | |
| Sheng et al. | The DnaJ domain of polyomavirus large T antigen is required to regulate Rb family tumor suppressor function | |
| JP2005516605A5 (enExample) | ||
| Leri et al. | Inhibition of p53 function prevents renin-angiotensin system activation and stretch-mediated myocyte apoptosis | |
| TWI497076B (zh) | 適合體及ｃ－反應蛋白檢測方法 | |
| Yuen et al. | Nonmuscle myosin is regulated during smooth muscle contraction | |
| Su’etsugu et al. | Molecular mechanism of DNA replication‐coupled inactivation of the initiator protein in Escherichia coli: interaction of DnaA with the sliding clamp‐loaded DNA and the sliding clamp‐Hda complex | |
| JP2005522999A5 (enExample) | ||
| Azad et al. | The multifunctional transcription factor Rap1: a regulator of yeast physiology | |
| RU2006126704A (ru) | Способы лечения астмы | |
| Cicchini et al. | Searching for DNA–protein interactions by lambda phage display | |
| JP2005507673A5 (enExample) | ||
| Parmacek | Transcriptional programs regulating vascular smooth muscle cell development and differentiation | |
| Labbé et al. | The alternatively spliced LRRFIP1 Isoform-1 is a key regulator of the Wnt/β-catenin transcription pathway | |
| Lue et al. | Site-specific immobilization of biotinylated proteins for protein microarray analysis | |
| JP2005512528A5 (enExample) | ||
| Salska et al. | Apelin and atrial fibrillation: the role in the arrhythmia recurrence prognosis | |
| Xiao et al. | Overexpression of genes by stress-responsive promoters increases protein secretion in Saccharomyces cerevisiae | |
| Wada et al. | The second largest subunit of mouse DNA polymerase ε, DPE2, interacts with SAP18 and recruits the Sin3 co-repressor protein to DNA | |
| Toft et al. | Rise of the terminator protein tus: A versatile tool in the biotechnologist's toolbox | |
| Marintchev | Exploring the interaction dynamics of eukaryotic translation initiation factor 2 | |
| Lau et al. | Trichomonas vaginalis initiator binding protein (IBP39) and RNA polymerase II large subunit carboxy terminal domain interaction | |
| Ge et al. | BPS2025-Differential modulation of beta-cardiac myosin conformations by cardiomyopathy-associated mutations in the converter domain | |
| CN108872586A (zh) | 一种定量检测srf的酶联免疫分析方法 |